Paying For Therapy – How To Use Hypnosis Tue, 06 Jul 2021 08:05:25 +0000 en-US hourly 1 Paying For Therapy – How To Use Hypnosis 32 32 Need disability services like therapy? Prepare for long waiting lists Wed, 30 Jun 2021 06:53:01 +0000 Jackson Dopp is nearly 21, a strapping young man who’s 6-foot-1 and weighs nearly 200 pounds. When he becomes agitated and runs down the street screaming, which happens often, one could easily misread the situation. His parents Jennie and Ryan Dopp, of Layton, Utah, have spent a lot of time telling neighbors, teachers, classmates, even […]]]>

Jackson Dopp is nearly 21, a strapping young man who’s 6-foot-1 and weighs nearly 200 pounds. When he becomes agitated and runs down the street screaming, which happens often, one could easily misread the situation.

His parents Jennie and Ryan Dopp, of Layton, Utah, have spent a lot of time telling neighbors, teachers, classmates, even the police, Jackson’s story before they meet him.

Jackson was born with a rare chromosome duplication, is on the autism spectrum and has attention deficit hyperactivity disorder, oppositional defiance disorder and anxiety. He’s always had trouble controlling his emotions and behaviors.

Although his parents and siblings love him dearly and his outbursts are less frequent now, his disabilities have left bruises: The Dopps have spent years feeling like they’re walking on eggshells, and Jennie Dopp says his siblings have post-traumatic stress.

With the exception of supports through the individualized education plan schools provide each student with a significant disability, the Dopps cope mostly on their own. Schools don’t address long-term needs like housing, transportation and medical care, which his family arranges. And children with disabilities may become independent only to a degree, if at all, so their families can face lifelong challenges. Jackson has limited ability to care for himself. Social skill and behavior therapy that might have helped when he was younger was hard to obtain then and insurance didn’t cover it. So the Dopps largely built their “own army of support” around him, his mom said, and feel fortunate they’ve had personal resources many families that include a person with a significant disability lack.

America has no comprehensive family support system, according to The Arc, an advocacy organization for people with intellectual and developmental disabilities. Most publicly funded support comes through Medicaid’s home and community-based service waivers. Some states add limited general fund dollars — a trickle of help in a desert of need, experts agree.

Jackson has been on a waiting list through one of Utah’s Medicaid waivers for home and community-based services since 2014 to address needs not related to his education. He is now No. 2,302 in line. States have different waivers and waiting lists. Nationally, 850,000 people with significant disabilities are waiting for community-based help without which they might be institutionalized.

Some of them may get that help, though parents who’ve waited sometimes a decade or more said they’re trying not to expect too much. President Joe Biden has included in his budget proposal $400 billion spread over multiple years to end waiting lists for community-based services.

Meanwhile, separately, a draft bill by U.S. Rep. Debbie Dingell, D-Mich., along with Sens. Maggie Hassan, D-N.H., Bob Casey, D-Pa., and Sherrod Brown, D-Ohio, would make at least some home and community-based services part of mainstream Medicaid, guaranteeing access for families who qualify., which covers disability news, said those measures could eliminate waiting lists and even let people with disabilities move from state to state without having to start over to join waiting lists for services.

“Jackson is just one boy,” his mother said. “There are thousands of other children just like him or with more significant challenges.”

She said being doomed to sit on a waiting list for years — even decades — harms individuals, their families and their communities.

What’s a home and community-based waiver?

The Medicaid waiver system was designed to provide services for people in dire need who might not otherwise qualify for Medicaid. The National Disability Navigator Resource Collaborative said waivers offer medically necessary services and supports so people who have chronic conditions serious enough to require an “institutional level of care,” can instead choose to live at home or in community settings and get appropriate help.

The Hill calls Medicaid “biased” toward institutional care, which must be provided if someone with disabilities qualifies. Individuals and families that choose to live in the community are often left out.

People served by waivers include children and adults with a range of challenges, from intellectual and developmental disabilities to severe physical disabilities, substance use disorders, age-related disabilities and mental health issues, among others, said Kaiser Family Foundation.

The waivers are a patchwork: notes 44 states have home and community-based waivers for people with developmental disabilities, but states have different definitions and rules. Some offer a combined waiver for developmental disabilities, which arise in childhood, and intellectual disabilities that occur in adulthood. There are other waivers, too. Utah, for example, has a physical disabilities waiver for those without use of at least two limbs, one for acquired brain injuries, another for children who are medically complex, a waiver for people who need technology to breathe, and more.

Waiver eligibility requirements can differ from general Medicaid eligibility.

There’s a lot at stake. “At some point, 70% of older adults will require help with dressing, hygiene, moving around, managing finances, taking medications, cooking, housekeeping and other daily needs,” said Disability Scoop, which notes by 2030, all 74 million baby boomers will be officially old. But people of all ages may have conditions that require significant assistance.

Texas has more than 200,000 people waiting. Some states have no wait. Within states, some waiting lists are longer than others, depending on the waiver category. Aging out of a child-targeted waiver can create a gap before adult services are available. Moving out of state can make a family start fresh on trying to access services — with new waiting lists and rules specific to a new location.

Some state lists are first come, first served; others prioritize on condition and need. The government list Jackson is on prioritizes need, so his position changes due to others’ needs, though “you get points for being listed for years,” said Joey Hanna, executive director of the Utah Parent Center, an advocacy organization.

Services are funded through a state-federal match, feds paying the lion share. If states don’t contribute, neither does the federal government. Utah hasn’t funded extra waiting list slots for a couple of years.

Some states are toying with trying a waiver that puts a cost cap on support. That wouldn’t meet all the needs, but might help more families, said Hanna.

Right now, families who reach the front of the waiver line to get services can access lots of help, so the difference between getting a waiver and being next in line is night and day in terms of support. And being on a waiting list doesn’t provide Medicaid coverage, but waiver placement does. “For those who don’t otherwise qualify for Medicaid or get a waiver, meeting needs can be “wildly expensive,” Hanna said.

The Dopps accidentally learned about the waivers. So far, knowledge has not been power. They dread the day in 2022 when Jackson’s no longer in school and the limited supports available there go away, too. Jennie Dopp said they fought to keep him in school until then; at one point his school tried to graduate him by giving him history credits for community outings, though he cannot safely cross a street alone. Budgets to provide services are finite and young adults with disabilities move on by age 22 if they haven’t graduated before.

What Congress could do

While campaigning for president, Biden proposed eliminating waiting lists and boosting the direct-care workforce. He included it in his infrastructure plan, saying “more people should have the opportunity to receive care at home, in a supportive community or from a loved one.” He vowed to boost service access and fund innovations in care.

The Republican counterproposal to his infrastructure plan didn’t include home and community-based services. But Biden included the $400 billion in his budget proposal, sent to Congress in May.

Advocates for people with disabilities say funding would benefit a larger group. Roughly 53 million people provide most of the care for frail elderly or disabled relatives, saving society lots of money. Financial services firm Genworth said assisted living center charges average $51,600 a year nationally, while a semiprivate nursing home room averages $93,075.

AARP, a national advocacy organization for seniors, said family caregivers average 24 hours a week providing unpaid care and spend about $7,000 out of pocket annually. Some must leave the workforce to provide care.

The National Health Law program, The Arc of the United States, the Autistic Self Advocacy Network, the Center for Public Representation and the Epilepsy Foundation hailed the bill that would make home and community-based services a mandatory piece of Medicaid. They said it would build on earlier efforts to ensure no individuals with disabilities or older adults are “forced to live segregated from their communities.”

They said ending institutional bias saves money. The average cost to serve a person with a disability in a publicly funded institution in those states that still have them is $294,300 per year compared to the average cost of services under a Medicaid home and community-based waiver, $49,854.

Expanding access would reduce waiting lists and improve services to those already benefitting, as well as address fissures in delivery of long-term care that were revealed by the pandemic, Nicole T. Jorwic, senior director of public policy at The Arc, told Deseret News. She said the funding could build a bridge for passage of the bill making home and community-based services mandatory in Medicaid, ending waiting lists entirely.

“All of these investments will mean more people with disabilities can receive services in their homes in communities, which is what they and their families want,” Jorwic said.

Families’ joys and sorrows

Matt McGhie’s 15-year-old son Charlie has multiple challenges, too: He is on the autism spectrum and also has near-daily seizures. McGhie and his wife take turns sleeping near Charlie so they can help him breathe when he has a seizure — sometimes 10 times a night. After a seizure, he may wander in a trance briefly until they can guide him back to bed.

His usually sunny, sociable personality can morph into aggression and angry outbursts — sometimes directed physically at his siblings and parents. “When he’s angry,” McGhie wrote on social media “the kids have learned to run and hide.”

Never have the McGhies, of Lehi, had access to services they didn’t pay for themselves or with help from relatives. They fought when he was little to get their insurance to cover autism. By the time the insurance agreed to cover services for children through age 7, Charlie was 8.

Charlie is No. 2,177 on a needs-based waiting list for services through Utah’s Division of Services for People with Disabilities. “That means there are 2,176 families ahead of us with needs greater than our own. They’re dealing with worse stuff than what I listed above, which is nearly breaking our family,” McGhie said. “That is rough.”

Several parents said they know families who couldn’t get services and eventually turned to institutional care when needs grew too big for them, including elderly parents who became too frail to physically manage. Hanna told of one mom in her 90s who showed up at the Utah Parent Center desperate for help with her 70-something daughter. The elderly woman was still caring for and lifting her.

Families hit different crisis points, including when a child with disabilities ages out of school and loses supports available there. Some parents quit jobs to provide supervision and care.

Hanna said advocates are pushing for people with disabilities to be able to work themselves, but that also requires support that may not be available.

Hanna’s family isn’t on a waiting list, able so far to manage care for their son, who is 15 and has disabilities. But summer will be hard: He’s too old for summer camp and they don’t know how they’ll work and juggle caring for him. He can’t be left alone long. She also knows many families have greater struggles.

“When families sit on waiting list with no services for years and years,” she said, “needs just get greater and greater. If you’re just kind of white-knuckling it and sitting on the waitlist, you’re not really able to build any capacity to plan.”

This attitude is common from strangers, said Hanna: “‘We’re sorry this happened and that your child was born with a disability, but it’s your responsibility to deal with it.’” As strong as families of those with disabilities are — “and there are no stronger people on this planet in my opinion,” she said — sometimes it’s too much, however willing parents are. And when parents die, the task passes to siblings — if there are any — conscripted sometimes willingly, sometimes not.

In the future, her son may need a waiver’s services. “Now that he’s a little bit older, I think we’re realizing that he has more challenges than we thought. We’ll work on getting him on the waiting list, but it’s not dire yet.”

Jackson, too, is better off than many with disabilities. The Dopps found him a job three days a week; some parents have children who could never work. He will not earn enough to support himself. While others his age date, marry and navigate adulthood, Jennie Dopp said those steps — while a possibility for Jackson — would look different and be difficult to attain.

The Dopps believe he’d thrive with a roommate or two and some supports. Without help, he’ll never reach his potential. Because he deeply absorbs the emotions of everyone around him, his mom doesn’t think he’d do well in a group home.

And like all parents with a child with life-limiting disabilities, they’re pondering what will happen if they grow frail or die. They’d feel better knowing Jackson had access to the services and supports he needs.

]]> 0
Bristol Myers takes a write-off of $ 470 million and waives the Orva-Cel CAR-T program Thu, 17 Jun 2021 21:52:03 +0000 Nitpicker / Shutterstock Earlier this week, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb‘s Breyanzi (Lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory (r / r) large B-cell lymphoma (LBCL) after two or more systemic lines of therapy. Liso-cel is a CD-19 targeted chimeric antigen receptor (CAR) T-cell therapy. The company […]]]>

Nitpicker / Shutterstock

Earlier this week, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb‘s Breyanzi (Lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory (r / r) large B-cell lymphoma (LBCL) after two or more systemic lines of therapy. Liso-cel is a CD-19 targeted chimeric antigen receptor (CAR) T-cell therapy.

The company also has a PDUFA date of March 31, 2021 for its Biologics License Application (BLA) for ide-cel, a B-cell maturation antigen (BCMA) targeted CAR-T therapy.

So it’s a bit of a surprise when Bristol Myers Squibb reported It abandoned a second BCMA CAR-T therapy, Orva-Cel, and took a $ 470 million write-off. Orva-cel was originally developed by Juno Therapeutics, which Celgene acquired for $ 9 billion before Celegene was acquired by Bristol Myers Squibb for $ 74 billion in late 2019.

The company’s head of drug development Samit Hirawat told analysts on a conference call last week that the decision would be to work with the best drugs, especially in a crowded field like BCMA.

“We have ide-cel as the front runner who has the data and has been submitted for review and approval in both the US and the EU,” said Hirawat. “If we look at the orva-cel development of the data and also look at it from the outside in relation to the landscape and the development of data, we believe that ide-cel fits perfectly with regard to further development. And the orva-cel platform will be very important for the next generation of CAR cell development and not for this particular drug itself. Therefore, we did not advance orva-cel as it is in its current form and would use the platform for the evolution of cell therapies. “

Orva-cel, short for Orvacabtagene Autoleucel, became rated in a Phase I / II EVOLVE study in mid-2020 to investigate different dose ranges of CAR T cells in patients with relapsed / refractory multiple myeloma (RRMM). Previous studies at lower doses showed an acceptable safety profile and promising clinical behavior.

At the time, Sham Mailankody, a medical oncologist at Memorial Sloan Kettering Cancer Center, said Helio, “BCMA has shown promise as a promising treatment target in myeloma, and Orva-cel is a novel CAR T-cell therapy with an optimized manufacturing process that enriches a central memory phenotype and could result in more sustained and hopefully more effective treatment in it Attitude. Initial data from the ongoing EVOLVE trial have shown promising efficacy for Orvacel treatment in patients with relapsed or refractory multiple myeloma. “

Liso-cel has been approved under the brand name Breyanzi. CAR T therapies like Breyanzi are live therapies in which T cells are taken from the patient, developed in a laboratory specifically for the patient’s cancer cells, and then re-infused into the patient where they grow and attack the cancer. It has a target lead time of 24 hours, with inpatient or outpatient management options. It is planned to roll out the therapy in a wide network of treatment centers that are certified for risk assessment and risk reduction strategy (REMS). Cytokine Release Syndrome (CRS) is as common as neurological toxicities, which is why the clinics that perform the treatments are REMS-certified so they are trained to deal with the potentially fatal side effects.

A Celgene Contingent Value Rights (CVR) of $ 9 as of December 31, 2020 Payout period passed. It was one of three required milestones for the CVR. Bristol Myers Squibb said at the time that the CVRs would then be terminated, meaning that they would no longer be solvent and could no longer be traded on the New York Stock Exchange. There were about 715 million CVR notes in circulation. If the three milestones had been met, the Notes would have paid out $ 6.4 billion to investors.

The CVR was based on FDA approval of three drugs, Zeposia, Ide-Cel and Liso-Cel. Ceposia (ozanimod) for the treatment of multiple sclerosis was approved in March 2020. The FDA accepted the approval application for biologics for ide-cel, a B-cell maturation antigen (BCMA) targeted CAR-T therapy, in September 2019 with a target deadline of March 31, 2021.

Liso-celo was originally supposed to be approved by November 16, 2020, but the pandemic blew the schedule. In November 2020, Bristol Myers Squibb stated that the COVID-19 pandemic was delaying travel for FDA inspectors to inspect a third-party manufacturing facility in Texas before the scheduled action date. But they couldn’t, a possible approval of Liso-Cel was delayed until the inspection could be completed.

]]> 0
Is ADHD a Learning Disability? Thu, 17 Jun 2021 21:52:03 +0000 ADHD can interfere with learning, but it is not a learning disability. Some challenging effects of the condition, such as difficulty concentrating and hyperactivity, can affect a person’s ability to learn. According to most researchers, and Organizations for people with learning disabilities, ADHD can interfere with learning and many people with ADHD have other learning […]]]>

ADHD can interfere with learning, but it is not a learning disability. Some challenging effects of the condition, such as difficulty concentrating and hyperactivity, can affect a person’s ability to learn.

According to most researchers, and Organizations for people with learning disabilities, ADHD can interfere with learning and many people with ADHD have other learning disabilities. However, because this condition does not affect certain aspects of education, such as the ability to understand language or the written word, doctors typically do not consider it a learning disorder.

Read on to learn more about why ADHD is not a learning disability, how it can still affect learning, and some management tips.

ADHD is not a learning disability. However, some of the symptoms can appear very similar to those of a learning disability. The rates of learning disabilities are also higher in children with ADHD, while children with learning disabilities are more likely to be diagnosed with ADHD.

The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) lists the following characteristics of specific learning disabilities:

  • There are persistent difficulties in writing, reading, arithmetic, arithmetic, or thinking during school years. In addition, children may have difficulty remembering facts, thinking clearly, or writing well.
  • A person’s academic skills appear below the average range. Here tests must use culturally and linguistically appropriate tests to qualify for a diagnosis. For example, a child with dyslexia has more reading difficulties and more effort to read than children without dyslexia.
  • Difficulties must begin during school time, not later in life.
  • Another disorder, such as a developmental or neurological problem, cannot better explain the symptoms. For example, a child with ADHD may have difficulty reading because of difficulty focusing, not dyslexia.

ADHD can affect many aspects of learning. The symptoms of this disorder and its effects on education can be lock in:

  • Reduced executive function: This makes it difficult for a person to plan and coordinate their thoughts and actions. A person may have trouble starting tasks, meeting task deadlines, and regulating their emotions.
  • Hyperactivity: People with ADHD may have trouble sitting still, waiting for their turn, or staying calm. This can make it difficult for them to succeed in class. It can also affect relationships with peers and teachers.
  • Difficulties in paying attention: People with ADHD can have difficulty staying focused in school, which can affect their ability to learn. Attention difficulties can cause a student to have difficulty passing good tests, even if they know the material. This is because distraction prevents them from completing the assessment or understanding the questions.
  • Disorganization: Disorganization can make it difficult for people with ADHD to learn or prioritize tasks. It can also cause them to miss deadlines and forget school assignments, which affects grades.
  • Impulsiveness: ADHD can lead to impulsive behavior – this can lead to a student getting into trouble at school. It can also lead them to make questionable decisions, such as: B. not studying or doing homework.
  • Lack of attention to detail: Students with ADHD may rush tasks or be unable to pay attention to small details. For example, you may not notice an extra word in a question or you may not fully read or understand a scientific paper.

It is important to note that while ADHD can be challenging, it also brings numerous benefits of the conditions, some of which could even positively affect learning, such as: B. Resilience and positivity.

Learn more about ADHD in relationships.

No single test can diagnose ADHD or a learning disability. Rather, doctors and psychiatrists rely on diagnostic criteria in the DSM-5 to diagnose both ADHD and learning disabilities. In addition, having just one symptom is not enough – a person must have several symptoms of diagnosis that interfere with daily life.

Some strategies for diagnosing these conditions include:

  • Body and health history: While a physical exam cannot diagnose ADHD or a learning disorder, it can rule out other causes such as a head injury or infection.
  • Academic history: A healthcare professional can ask about a student’s academic performance to assess the areas that are most difficult for them to find. For example, a high-grade child who has difficulty reading only may have a reading-related learning disorder, such as dyslexia.
  • Neuropsychological tests: A doctor may give a child multiple tests to assess alertness, check for specific learning disabilities, and identify differences in thinking or learning.
  • Development history: Because of the genetic components of learning disabilities and ADHD, a doctor may ask about a family history of the diseases. To diagnose a child or adult with ADHD, a doctor wants to see evidence of ADHD symptoms at multiple stages of development and in different contexts.

Treating ADHD can help with learning-related symptoms. Try it following strategies:

  • Let parents and teachers know about ADHD: Support for adults Caring for children with ADHD can help them manage their symptoms better.
  • Experiment with ADHD Management Strategies: Frequent reminders, calendar apps, a planner, or a special place to keep all of your school books can reduce forgetfulness and stress.
  • Consider therapy: Psychotherapy can help a person learn to live with ADHD, develop coping strategies, and be more effective about their needs in school.
  • Consider medication if the person with ADHD is older than 6 years: Stimulant medications can help a person focus, which can enable them to self-actualize in school.
  • Use a comprehensive approach to treatment: The American Academy of Pediatrics recommends using stimulant drugs in children under 6 years of age only when other interventions are not working. A combination of interventions works best at any age.
  • Lawyer for a individualized education plan: Work with teachers to develop a personalized curriculum. As part of this plan, encourage school accommodations such as B. a distraction-free test environment. Although ADHD is not a learning disorder, people with the condition generally have protection from it Law on People with Disabilities in Educationwhich entitles them to certain accommodation in the school.

A person cannot self-diagnose ADHD or any other learning disability – a professional needs to assess their symptoms and rule out other underlying health conditions.

In most families, diagnosis begins with the family pediatrician, who can turn to an ADHD specialist such as a psychiatrist or mental health advisor. A person can also independently search for their own mental health provider and request an appointment.

Seek help with ADHD or learning disabilities if a person:

  • thinks they may have ADHD or a learning disability
  • notes that treatment for ADHD is ineffective
  • needs special accommodations in the school
  • develops unbearable side effects associated with ADHD drugs

ADHD is not a learning disability as it does not affect a person’s ability to learn certain skills such as reading, writing, or math.

However, some effects of ADHD, such as difficulty concentrating, can lead to some learning difficulties.

The condition can make learning difficult, but it doesn’t have to stop a person’s academic dreams. People with ADHD can become successful learners and achieve great things in science.

With the right combination of treatment and support, people with ADHD can thrive in environments that require close attention and rest.

]]> 0
Is Behavior Therapy an Effective Treatment for ADHD? Thu, 17 Jun 2021 21:52:03 +0000 Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that can affect behavior. Behavioral therapy can help manage ADHD symptoms by promoting helpful change and improving self-control and self-esteem. Treatments for ADHD usually include Medication and psychotherapy. Behavioral therapy is a form of psychotherapy that can help a person with ADHD develop or improve a […]]]>

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that can affect behavior. Behavioral therapy can help manage ADHD symptoms by promoting helpful change and improving self-control and self-esteem.

Treatments for ADHD usually include Medication and psychotherapy. Behavioral therapy is a form of psychotherapy that can help a person with ADHD develop or improve a variety of skills to deal with behavioral challenges. It can also help parents and other caregivers develop constructive ways to respond to children with ADHD.

The effectiveness of therapy varies from person to person, and a doctor may also recommend medications to get the best results.

In this article, we will describe what behavior therapy is, how effective it is for ADHD, and what techniques different types of behavior therapy use.

Behavioral therapy is an umbrella term for various forms of therapy that focus on a person’s behavior.

The aim is to help a person to recognize unhealthy or harmful behavior and change this by adopting helpful behaviors instead. It is based on the idea that a person learns behavior patterns and therefore can learn new ones, although learning and reinforcing these behaviors can take time.

Common forms of behavior therapy can include cognitive behavior therapy (CBT) and dialectical behavior therapy (DBT).

Certain behaviors related to ADHD can be disruptive and challenging. medication can help Control the core symptoms during behavior therapy aims teach or improve helpful coping skills and strategies.

Different forms of behavior therapy can help a person:

  • stay focused longer
  • Organize thoughts and tasks
  • Reduce procrastination
  • Avoid hyperactivity when it is inappropriate
  • Recognize and correct impulsive actions

While research is often in the early stages, there is growing evidence that behavior therapy is an effective part of ADHD treatment.

The Centers for Disease Control and Prevention (CDC) For example, note that parenting and behavioral training in young children with ADHD can help with symptoms. This may require caregivers, teachers, and therapists to work together to establish rules and define positive behaviors.

A Study 2016, meanwhile, found that CBT was an effective treatment for adolescents with ADHD who did not respond well to medication. A similar Study 2018 concluded that college students with ADHD will benefit from CBT. The researchers reported that participants had less severe symptoms and improved “leadership,” a wide range of skills that help people complete tasks, manage time, and control emotions and behavior.

Adults with ADHD can too respond well to CBT. A Review 2016For example, there was growing evidence that CBT can relieve symptoms in adults.

In addition, there are adults with ADHD more likely Experiencing anxiety and depression that can be addressed with CBT.

Learn more about ADHD and relationships here.

As the research cited above suggests, some form of behavior therapy can benefit a person of any age with ADHD – and it can help caregivers, too.

For example, the CDC reports that basic behavioral therapy training can be useful for caregivers of children under the age of 12 with ADHD. Training can teach parents and other caregivers to provide the structure and support the child needs, as well as teaching the child helpful behavior.

The age at which a child is ready for their own therapist can vary, but the average age is around 8-10 years old. From that point on into adulthood, a person can work directly with a therapist to help them achieve their behavioral goals.

There are many forms of behavior therapy, and the most effective will depend on each person’s specific factors. Someone with ADHD might consider:


This focuses on a person’s thoughts and behaviors. It can activate a person to change negative thought patterns into positive ones by changing the way they see challenges. It can help people with ADHD find more effective approaches to time management, organization, planning, and impulse control. CBT can also help a person find more useful ways to deal with emotions and stress.


This helps people tolerate and regulate their emotions. The goal of DBT is to teach people techniques that will help them understand their emotions, as well as applicable ways to manage emotions and change their behavior. That can help prevent impulsive or self-destructive behavior patterns.


This is a hands-on intervention that specifically targets areas of difficulty for a person with ADHD – areas such as planning, time management, goal setting, organization, and problem solving. Coaches impart practical skills to teach People with ADHD how to overcome these challenges.


This involves measuring brain activity and trying to change it to reduce symptoms of ADHD. People with ADHD usually show less activity in areas of the brain associated with personality, behavior, and learning. Neurofeedback aims to change behavior by increasing activity in these areas of the brain.

Learn more about neurofeedback in ADHD.

Although each method of behavior therapy is different, they overlap in the use of operant and classical conditioning techniques.

Operant conditioning is based on reinforcement. It aims to teach positive behaviors and reward for doing them more likely happen. Classical conditioning is a learning process in which people associate two stimuli in order to achieve a certain effect. For example, associate a certain sound with sleep can help a person feels sleepy after hearing this sound.

After identifying problematic behavior, a person and their therapist can develop a plan to address it and replace positive behavior. This could include a reward for switching to the more helpful behavior and consequences for continuing the problematic behavior.

A child with ADHD can benefit from a goal chart. Showing positive behavior brings the child one step closer to a reward on the chart, while problematic behavior sets them back. Seeing your progress can give a child a sense of accomplishment as they work toward their goal.

Behavioral therapy for ADHD isn’t a quick fix; It takes time and discipline to see results.

Changing thoughts and behavior patterns takes regular effort, and while setting time limits on certain milestones can be helpful, the pace of progress will depend on factors specific to each person and how effective the treatment is for them is.

By working closely with a therapist, people with ADHD can see improvements in symptoms and feel more in control. Even after improvements have been seen, it is important to stay consistent with the reward and consequence system to avoid relapses.

doctors often recommend Behavioral therapy for ADHD alongside other treatments, such as B. Medicines. Drugs, whether stimulating or not, can target the neurological component of the disease, for example by increasing levels of important neurotransmitters in the brain.

Behavioral therapy can work well as a complement to medication, especially if medication alone is ineffective.

Behavioral therapy for ADHD involves identifying problem behaviors and working to replace positive behaviors. Research suggests behavior therapy is an effective way to manage symptoms of ADHD in children, adolescents, and adults.

A doctor may suggest that a person with ADHD also take medication for the most effective results.

]]> 0
‘In Treatment’, ‘Run the World’ among TV series normalizing therapy Thu, 17 Jun 2021 21:52:03 +0000 Thirty years ago, watching a character on television visit a therapist was often made fun of. At least that’s how Yvette Lee Bowser, then executive producer of A Different World, remembers it. There was still a stigma in the real world about seeking such mental health care, especially in the African American community, she notes. […]]]>

Thirty years ago, watching a character on television visit a therapist was often made fun of. At least that’s how Yvette Lee Bowser, then executive producer of A Different World, remembers it. There was still a stigma in the real world about seeking such mental health care, especially in the African American community, she notes.

Only five years later, when Bowser was working on “Living Single”, she was able to take up the therapy conversation again with a slightly different tone, because “Society, like our writing staff, was in a place where we wanted to help him to normalize”. . “

With talk therapy now a part of many people’s health journey, it will be featured as such in a number of new screenplay series by Starz ‘Rule the world“Which Bowser Executive produces, to showtimes” Black Monday “and more dramatic works like HBO’s” Mare of Easttown “and the return of”In treatment. ”And since therapy entered the public debate, authenticity in storytelling is more important than ever.

“What we do as writers and storytellers is to provide cultural mirrors, so we wanted society to see itself able to go to therapy and be comfortable with it,” says Bowser. “And now we’re in a place where it’s the norm, so we dealt with it at Run the World: it’s just something they do as part of their self-care routine. And you can’t really be healthy without taking care of your mental health. “

On NBC’s “Zoey’s Extraordinary Playlist,” however, the title character (played by Jane Levy) enters therapy for the first time in season two because she realizes she’s so in tune with the feelings of others (admittedly, because of a metaphysical ability). hearing these feelings as songs) but not their own. She confesses this “superpower” to her therapist (played by Oscar Nunez), who takes her very seriously.

“It was really about, ‘Who do we go to in an emergency and who do we turn to for help?'” Says showrunner Austin Winsberg. “The first thing I wanted to make sure was that it was based on some kind of reality or truth. It’s not his job to judge, it’s just his job to listen and help. “

Dr. Helen Land, associate professor at USC, notes that there have been some “fairly problematic” televised depictions of therapy, even the original version of “In Treatment,” whose psychotherapist Paul (Gabriel Byrne), she says, occasionally exhibited “inappropriate behavior” towards customers. TV therapists “often push boundaries,” she says. The writers, producers, directors and actors of the shows “have to be very careful”.

For example, sometimes a therapist character talks about himself in a session scene to encourage interpersonal dynamics or to reveal a surprising commonality between the doctor and patient, to create a connection or simply to move the action forward. But dr. Land advises that licensed therapists “don’t share anything about things” [themselves] unless it is psychotherapeutic for the individual. ”Due to the HIPAA rules, they also do not share information about customers with another person, unless [they] Have a permit signed for a certain period of time. “

Another common misconception spread through television can be the level of education a person must have in the position they hold (“Having a bachelor’s degree in psychology doesn’t equip someone to do all about personality and profiling etc. ”explains Dr. Land) as well as confusing diagnoses.

Of course, the best way to avoid these missteps is to “hire a well-accredited therapist to review the information in the scripts”.

For the new version of “In Treatment”, co-showrunners Joshua Allen and Jennifer Schuur did just that. They hired a black therapist who had her own practice in New York City, says Schuur, as a counselor to convey the “really specific point of view” they wanted for their new character, Dr. Brooke Taylor (Uzo Aduba), needed as to some of the nuances of the work that would be done in their sessions. Equally important for her was to show what talk therapy is (including differentiating what makes Brooke different from what a psychiatrist who can prescribe medication would do for a client) and “who has access to it and what it can do” , Allen says.

“I think there is this Woody Allenish idea of ​​who goes to therapy, what therapy is for – that you only go when you are in a crisis and the label ‘You only have to see a therapist if you have a disorder has’ .’ We wanted to take the wool off, ”he continues. “Brooke has to reset expectations very early on: ‘If I start scratching and find something, I’ll keep going. We have no goal in mind. ‘”

Likewise, many such therapies do not have an end date or a promised schedule for “breakthrough” moments. Everyone has learned that if a doctor or client wants to end treatment, “professionally and ethically” a better course of action is to end it together than “flip a switch and say, ‘OK, see you never.'”

Dr. Land also emphasizes that people who go to therapy are often “very vulnerable” but they have the right to refuse to “go where the therapist wants to go” in sessions or further sessions. “We need informed consent to treatment,” she says. “We are employed by them.”

As the discussion about the importance of mental health grows in a world that will hopefully soon be a post-pandemic, Bowser notes that someone on the screen is “working on their individual problems as well as their problems with one another” on a universal level assignable. Hopefully, if the audience see themselves reflected in the fictional therapy sessions, that will inspire them to talk to someone too.

“We didn’t want to try to bring people to therapy. says Schuur. “But I think what we’re addressing at the core of these characters’ problems is the biggest things, namely about identity, self-worth, your story and how it shapes who you are and why you are who you are – that’s them deepest things that you can achieve in therapy. Ultimately, you go away, know more about yourself, and then move around the world [in a way] that is more authentic and true for you and you alone. Our goal was to show that this is the hope of therapy. “

]]> 0
The cost watchdog ICER will bless some high-priced gene and cell therapies, but only with solid proof of benefit: Analyst Thu, 17 Jun 2021 21:52:03 +0000 On the surface, it may seem that the higher the price of a new drug, the harder it is for its developer to get a thumbs up from the Institute for Clinical and Economic Review (ICER). For companies in the fast-growing area of ​​gene and cell therapy, this would make the ICER review a difficult […]]]>

On the surface, it may seem that the higher the price of a new drug, the harder it is for its developer to get a thumbs up from the Institute for Clinical and Economic Review (ICER). For companies in the fast-growing area of ​​gene and cell therapy, this would make the ICER review a difficult hurdle, especially if the agency’s opinions gain more weight in the future when deciding on insurance coverage.

However, Mizuho Securities analysts have looked at most of the ICER’s previous judgments on gene and cell therapies and identified a surprising trend: the institute’s reviewers rated more than half of the products tested to date as inexpensive. And the evidence they used to reach these positive conclusions provides important research, development, and pricing lessons for next-generation gene and cell therapy developers, said analyst Difei Yang, Ph.D., lead author of two reports that Mizuho sent customers in an interview last week.

“Of course they pay attention to the time that the patient gains, but also to the quality of life,” said Yang. Companies struggling to provide robust data showing that gene or cell therapy could outperform standard of care for either treatment – direct studies, solid evidence of long-term benefit, etc. – were more likely to receive a positive ICER judgment Economy, thought Mizuho.

Manufacturers of CAR-T cancer cell therapies have so far been much more successful in proving superiority over the standard of care than manufacturers of gene therapies for rare diseases, Mizuho noted. ICER confirmed the cost effectiveness of the first two CAR-Ts on the market, Gilead’s Yescarta for lymphoma and Novartis’ Kymriah for lymphoma and leukemia, both approved in 2017 and retailed for $ 373,000 and $ 475,000, respectively. And the agency has already announced that it will give the thumbs up to the previously unapproved CAR-T-Cilta-Cel with multiple myeloma from Janssen and Legend Biotech – assuming it costs $ 475,000 or less.

Only one in four CAR-Ts that ICER reviewed failed to meet the cost-benefit line: Bristol Myers Squibbs Ide-Cel for multiple myeloma, that was started this spring with the brand name Abecma priced at $ 419,500. A spokesman for BMS complained at the time that ICER relied on “inadequate modeling of overall survival data from ide-cel and a misguided view of re-treatment”.

ICER President Steve Pearson, MD, quoted “Major evidence gaps” in the data available to the agency while reviewing the cost-effectiveness of multiple myeloma treatments.

Pearson said in an interview that ICER reviewers sometimes struggle to determine how to translate data from often brief studies into real results. “We need to see longer-term data that we can relate to what we see in the short-term,” Pearson said. “What we really want to see are patient-relevant results, such as their functionality and their quality of life.”

Companies are often inadequate when it comes to providing data that clearly contrasts patients who receive gene or cell therapies and those who don’t, Pearson said. “You say maybe [non-treated] Patients only have six months to live, but sometimes the comparison just isn’t that clear, ”he said. “[Or] the [standard-of-care] Data can be 10 years old. We know that care will change over 10 years. “

BMS took a step in this direction with another CAR-T in its portfolio, Breyanzi, which was approved for large B-cell lymphoma in February. The trial version was released last week Data showed an improvement in event-free survival in patients receiving CAR-T treatment compared to those treated with Roche’s gold standard Rituxan, high-dose chemotherapy, and stem cell transplantation.

It’s too early to define Breyanzi’s ability to prolong life, but BMS hopes the data will ultimately move the CAR-T earlier in the treatment plan and differentiate the product from lymphoma rivals Yescarta and Kymriah. Breyanzi was introduced at a list price of $ 410,300. ICER has not yet reviewed the product.

Yang von Mizuho says the opportunity to get the green light for earlier treatment could motivate such head-to-head studies, and ultimately, those data would likely bring ICER on board with high-priced cell and gene therapies as well. “The sooner you treat the patient, the better off he is. And the better they are, the lower the net cost to the health system, ”she says.

CONNECTED: Bristol’s new myeloma CAR-T needs a hefty discount to be cost-effective, watchdogs say, while advocating GSK’s Blenrep

On the other hand, gene therapies from ICER have received mixed ratings for cost-effectiveness. Take Spark Therapeutics’ Luxturna, which is approved for a rare hereditary condition that causes blindness in people one year and older. ICER determined that the product that started at $ 850,000, it would be cost-effective if it were given to patients aged three years, but not if given to patients aged 15 or later, since by then they would have lost a significant amount of their vision.

Yang attributed the verdict to the cost of nursing care. “ICER tries to quantify how much a caregiver costs. So if the child is treated earlier, the idea would be that they are more independent and require less care, ”says Yang. “By the time they are treated at 15, much of that cost has already been incurred. And this message is in line with gene therapy in general. “

However, Pearson said ICER’s reviewers placed more emphasis on the overall value of preventing blindness to society. “There really are no health costs to speak of when you’re blind,” he said. “But society saves money to some extent because training costs are lower, patients have full career opportunities and higher earning potential when they see fully.”

ICER initially resisted Novartis’ $ 2.1 million gene therapy for spinal muscular atrophy (SMA), Zolgensma, but also refused to approve Biogen’s SMA drug Spinraza. Spinraza kicked off at up to $ 750,000 each year thereafter for the first year and a half, which eventually led ICER to determine Zolgensma is the lesser of two evils in terms of cost.

BioMarin’s Roctavian, a haemophilia gene therapy, cleared some hurdles on the road to approval, but ICER has already determined how it would be cost-effective. At a wildcard price of $ 2.5 million, ICER estimates that if gene therapy lasted for a dozen years, it would save the healthcare system about $ 5 million per patient compared to chronically dosed factor VIII. “This is an example of where gene therapy can really be doomed [costs]”Said Yang.

CONNECTED: ICER’s damn pharmaceutical awards for years, but now drug makers are rolling up their sleeves to cooperate

After looking into ICER’s methodology, Yang said she had a bone to choose with the agency. “Right now, their judgments are based on clinical evaluation, but the value of innovation should be considered in some way,” she said. “We learn something in the process, and it has to be permanent. I don’t think that will be recorded. “

Pearson’s answer? “We are sensitive to the idea that treatments with different approaches are useful, but we don’t see innovation as something separate from the benefits to patients and families,” he said. “Innovation is important to patients in that it helps them lead better lives. If it’s not better for the patients, I’m not sure we should pay more for it. “

ICER recently stepped up efforts to maintain an ongoing dialogue with biopharmaceutical developers and insurance companies. The agency has adopted a “formal 12-month checkup” policy for each of its published reports, Pearson said. If new data was released during this time, the reviewers can reconsider their original judgment.

It also introduced ICER Analytics, a cloud-based portal that houses all of its economic models. Life science companies and insurers can subscribe to ICER Analytics. “If [a drugmaker] Has new evidence or if they disagreed with our assumptions the first time, they can fill in their own information and get a different result at a fair price, ”Pearson said. “We’re going to put this together with our original results for payers to see.” More than 50 companies have signed up for trial subscriptions since ICER Analytics launched in November, he said.

]]> 0
Think twice before giving the COVID-Vax Gi to healthy children Thu, 17 Jun 2021 21:52:03 +0000 The case of vaccinating children is There, but it is not mandatory at the moment. The delta variant (B.1.617.2) could change the calculation, depending on upcoming data from Great Britain, Singapore and India, where the variant may show more contagious and virulent properties in younger people. By now we should all know that it is […]]]>

The case of vaccinating children is There, but it is not mandatory at the moment. The delta variant (B.1.617.2) could change the calculation, depending on upcoming data from Great Britain, Singapore and India, where the variant may show more contagious and virulent properties in younger people. By now we should all know that it is important to be humble when dealing with this virus. An increase in cases in the UK in the past few days is worrying and should be followed closely by us.

To return to the current discussion of the risk of COVID-19 for children (ages 0-12), it is worth summarizing the best data available so far. Reading through medical literature and news reports, and speaking to pediatricians across the country, I have not yet come across a single healthy child in the United States who has died of COVID-19. To investigate further, my research team at Johns Hopkins partnered with FAIR Health to study Pediatric COVID-19 deaths, accounting for roughly half of the country’s health insurance data. We found that 100% of pediatric COVID-19 deaths were in children with a pre-existing medical history, solidifying the case to vaccinate any child with a comorbidity.

Since the risk of a healthy Child deaths are extremely rare between zero and negligible. It is understandable that many parents rightly ask why healthy children are vaccinated at all?

For these parents, I would say that the main reason for giving the vaccine to a healthy child is not to save his or her life, but to prevent the Multisystem Inflammatory Syndrome (MIS-C)which can be painful and have long-term health consequences. According to the CDC, there was 4,018 cases from MIS-C to COVID-19 with an average age of 9 years. A total of 36 children died. Cases of MIS-C were largely shifted to minority children (62% were Hispanic / Latino or Black), likely due to the disproportionate rates of obesity and chronic illness among children in these populations. This finding again supports the COVID-19 vaccination in every child with an illness, including obesity.

It is also important to note that the risk of exposure to COVID-19 in children is not linear over time. Since the new COVID-19 case rates began rapidly declining in Maywho has had the weekly rate of new cases of MIS-C related to COVID-19-19 dropped to zero. And this week, a CDC report Regarding hospitalizations of children due to COVID-19 in March and April 2021, there were no deaths in the entire cohort of children studied.

There is an argument for vaccinating children to create community benefit for children. Vaccinating healthy children can help reduce virus transmission to children at risk who choose not to be vaccinated or others who cannot receive the vaccine. On the other hand, data from Israel suggests that high vaccination rates in adults significantly reduce transmission among children – a trend that is now being seen in the United States. We also know that compared to adults, children are inefficient carriers of COVID-19. That could possibly change with new information about the latest Delta variant, but it has not yet been.

The extremely low chance of benefit to healthy children is precisely why pediatricians like Richard Malley, MD, of Harvard, and Adam Finn, MD, PhD, of the University of Bristol passionately written “Not to use valuable coronavirus vaccines in healthy children”. One recently editorial in the The BMJ repeated this feeling – also an argument eloquently articulated by Medpage‘s own Vinay Prasad, MD, MPH. From a global perspective, two doses of a globally scarce, life-saving vaccine could be more equitably used to immunize a 65-year-old couple in India or Brazil (one dose per person) rather than giving both doses to a single one. one year old healthy child. Accordingly, California’s announcement is to be spent $ 116 million Paying people to get the vaccine when much of the world is begging for it amid angry epidemics is a sad comment on the excesses, injustice and ethnocentrism of our country.

Children can also experience unique side effects from the second dose of COVID-19 vaccine onwards. Seven adolescent children were there reported develop myocarditis within 4 days of receiving the second dose of Pfizer vaccine. All were boys between the ages of 16 and 19. Both mRNA vaccines were shown to be 100% effective in preventing COVID-19 in children. But every time a drug is found to be 100% effective, the question should be raised of whether the dose is too high, the interval too short, or whether the second dose is needed at all. Pfizer is now considering lower vaccination doses for children as they mentioned Tuesday in their announcement that they will begin their vaccine study in children under the age of 12.

It is important that immunity is not only conferred by antibodies, but also a function of by B and T memory cellsthat can be suggested by the study researchers long lasting immunity. Given the near zero risk of COVID-19 death in healthy children and the recent discovery of rare myocarditis complications immediately after the second dose, this should spark a discussion of whether a single dose is the more appropriate approach for healthy children.

In my residency training, I was taught an old dictum that many of you may be familiar with: “When you donate blood to someone, always give at least two units.” It took decades for the medical community to reverse this dogma. We now understand that a second unit of blood causes rare but real harm. We have come to realize that one unit is safer than two when a second unit is not required. We should also give up the idea that the vaccine must always be given in two doses. For transplant patients, for example, there can be three. In children with a natural immunity to previous infection, it may not be.

What about children who have been confirmed to have COVID-19 infection in the past? I would recommend avoiding a COVID-19 vaccination. If one looks at the natural immunity in adults for comparison, so Observational and empirical data are overwhelming: the natural immunity is real and it works.

Cleveland Clinic researchers published a study This week it was found that “none of the 1,359 previously infected subjects who remained unvaccinated had SARS-CoV-2 infection for the duration of the study.” This is one of many studies showing that natural immunity is strong. While the long-term stability of natural immunity is unknown, it is also unknown for vaccinated immunity. We can positively postulate with convincing arguments, but to be true to science we don’t have any data beyond 18 months for either. In fact, there is more follow-up data on natural immunity than on vaccinated immunity. Based on Collecting data, Children who have had COVID-19 should not be vaccinated unless they are immunocompromised.

A final and minor consideration should be fear of needles, which has no or minimal impact in most children but can be traumatic for some. For children who should receive the vaccine and who also have fear of needles, cold therapy, and vibration devices such as: “Buzzy” device, can be applied to the skin injection site prior to injection and results in little to none Pain.

In my opinion, the COVID-19 vaccination makes sense for every child who is overweight or who has a previous illness. It can also make sense for a teenage boy, as they have a greater physiological resemblance to adults, and that vaccines that are safe in adults were safe in children when properly dosed. But given the rarity of a healthy child dying from COVID-19, I wouldn’t recommend a two-dose vaccination to a healthy child aged 0-12 until we have more data. Each parent has to assess the individual risk of their own child, but in my opinion vaccination of young healthy children is not currently mandatory.

Marty Makary, MD, MPH, is the editor-in-chief of MedPage today and Professor at the Johns Hopkins School of Medicine, Bloomberg School of Public Health, and Carey Business School. He is the author of The price we pay.

Last updated on June 10, 2021

]]> 0
Meza submits invoices for conversion therapy Thu, 17 Jun 2021 21:52:03 +0000 The following article is a press release from the Office of State Rep. Terry Meza. AUSTIN – State Rep. Terry Meza (D-Irving) announced this week that she has submitted the final bill in a package of three that she submitted to address the practice of so-called “conversion therapy” in Texas. Meza’s invoices regulate the legality […]]]>

The following article is a press release from the Office of State Rep. Terry Meza.

AUSTIN – State Rep. Terry Meza (D-Irving) announced this week that she has submitted the final bill in a package of three that she submitted to address the practice of so-called “conversion therapy” in Texas.

Meza’s invoices regulate the legality and permissibility of the therapy itself and the reimbursement of the practice by the health insurance company.

House Bill 2516 would prohibit any public or private health insurance company operating or selling policies to Texan consumers from paying for or reimbursing conversion therapies, whether that therapy is provided by a licensed professional or an unlicensed provider. It would also prohibit the state Medicaid program and the Medicaid managed care program from funding conversion therapy.

Meza’s House Bill 2753 prohibits any government agency from a local water authority to a county, county, or state of Texas from purchasing health insurance that reimburses or pays for conversion therapy for their employees.

House Bill 3196 would prohibit regulated nonprofits from offering any type of conversion therapy, regardless of whether it is offered by licensed or unlicensed professionals.

If a nonprofit allows a health care provider or unlicensed individual to conduct conversion therapy through that facility, the Texas Secretary of State could terminate the applicant facility under the Meza bill. In addition, such a company would lose the franchise tax exemption under the Texas Tax Code.

“Most legitimate, licensed, and regulated medical providers don’t offer conversion therapy,” noted Meza. “It is often less regulated entities like nonprofits that are still making this harmful practice accessible to Texas families,” she noted. “Just like a Fortune 500 company, nonprofits are organized under state and federal nonprofit law,” Meza continued. “If a nonprofit allows someone to offer conversion therapy under their umbrella, by my calculations, they forfeit their right to operate in Texas,” she continued.

“After following the topic of conversion therapy for some time, it was important to me that we deal with the practice of unlicensed individuals and those who operate under the umbrella of non-profit organizations.” said Meza.

Regarding her other bills, Meza noted that the best way to reduce their use is to make sure insurance companies don’t cover the cost of conversion therapy if it doesn’t make the practice illegal in Texas.

“I have two bills on this subject. One prohibits any insurance company operating in Texas from paying for conversion therapies. “Texas is a very big marketplace for companies that want to insure government employees,” said Meza. “To do business with Texas government agencies, insurance companies would have to stop paying for conversion therapy if my bill went through,” she noted. “In my view, this would result in a significant decline in conversion therapy insurance policies in the public and private sectors as most insurance companies simply stop paying for a practice when their largest customers are legally prohibited from buying their policies when they do cover them, ”she remarked.

Considered a pseudoscientific practice, conversion therapy is a type of therapy that purports to change a person’s sexual orientation from homosexual or bisexual to heterosexual by using a variety of psychological, physical, and religious or spiritual methods. The practice is viewed by most mental illness providers as ineffective and harmful. The American Psychiatric Association opposes and has banned treatment among its members because it is based on the assumption that a person’s sexuality is a mental disorder and the practice of conversion therapy is unethical. In addition, the American Academy of Child and Adolescent Psychiatry, the American Academy of Pediatrics, the American Medical Association, and the American College of Physicians and other medical associations have also condemned the practice.

New Mexico, California, Washington, Oregon, Utah, Illinois, Virginia, New York, Maine, Vermont, New Hampshire, New Jersey, Rhode Island, Hawaii, Maryland, New Hampshire, Massachusetts, and Colorado prohibit the practice. Various counties and parishes including Cincinnati, Ohio; Miami, Florida; Columbus, Ohio; Philadelphia, Pennsylvania; and Pima County, Arizona also ban the practice.

State Rep. Terry Meza represents Irving and Grand Prairie in their second term in the Texas legislature. Rep. Meza is from Irving and is one of a small handful of former public school teachers who have seats in the Texas House of Representatives. She is a member of the Committee on Human Services, the Committee on Public Education and the Committee on Resolutions Calendars. Meza is a member of the Texas House Democratic Caucus on the Texas Democratic Party Executive Committee and the HDC Steering Committee.

]]> 0
Documentary about the life of blues legend Buddy Guy premieres at the Tribeca Film Festival Thu, 17 Jun 2021 21:52:02 +0000 “Funny thing about the blues: You play them because you have them. But if you play it, you lose it. ”The words of Buddy guy in his documentary, Blues Chase The Blues Away, perfectly describes how the power of music is perhaps the most transformative expression and self-therapy for the black man and woman in […]]]>

“Funny thing about the blues: You play them because you have them. But if you play it, you lose it. ”The words of Buddy guy in his documentary, Blues Chase The Blues Away, perfectly describes how the power of music is perhaps the most transformative expression and self-therapy for the black man and woman in America.

The sound of the blues, which emerged from its gospel roots in the cotton fields of American slavery, is a foundation for almost all varieties of popular music of the 20th and 21st centuries – from rock & roll to jazz to R&B. Lots of the rousing guitar licks you’ve heard of Jimi Hendrix, Eddie Hazel, Ernie Isley as well as slash, Lenny Kravitz and others are more likely to be attributed to Guy’s influence.

(Photo credit: Tribeca Film Festival)

It took three directors – Devin Amar, Charles Todd, and Matt Mitchener – to cover 84 years of the life of this legendary musician. However, they give Guy the space to tell his own story. From picking cotton as the son of tenant parents in Lettsworth, Louisiana, to the clubs of Chicago, Illinois, to sidemaning some of the biggest names in the blues, to being an inspirational agent to the most famous rock and rock acts to ever come from Britain.

The opening is as divine as it is humble. While standing alone in a field in Louisiana, we learn of Guy’s most important musical inspirations as a child; the birds and John Lee Hooker. Knowing that a man with a fiery stage presence and burning hoes was first influenced by nature and then the guttural songs of Hooker makes perfect sense.

The film is beautifully edited, marbled interview material, oil paintings, and old-fashioned analog film rolls from the early 20th century. It subtly tells the viewer how much time and changes Guy has witnessed.

But a recurring theme in the film is that Guy was a humble man; a man more interested in watching and listening to his heroes like Willie Dixon, BB King and Lightning Hopkins than joining them.

What got Guy on the road to success was desperation. He explains how he was once fired from a blues gig in Baton Rouge for being too scared to sing in front of more than four people but was eventually forced to overcome his fear by literally going to the 1957 for his dinner Chicago 708 Club sang.

After stranded in the city, he fled with no job and no money, his guitar playing and singing caught the legend’s attention Muddy water who made him a salami sandwich that night and got him on his way as a professional blues man.

Guy built his reputation in the Chicago clubs by simply standing up. He differed from his peers and mentors, who were used to sitting on chairs and stools, but stood out in that he stood up and played his solos with ruthless devotion.

Buddy Guy Tribeca
(Credit: Screenshot / Tribeca Film Festival)

He soon started playing pages for records on acts like Dixon and Junior Wells while during the day he drove a tow truck but was forced to rule in his fiery game of Chess Records, even though he knew how his heroes played but knew what was inside of him. “I could play her style,” said Guy. “I could fly to the moon. But I could also fly to Mars. “

“You have to be a badass if you come up with something that people are still trying to copy decades later,” said Gary clark jr, talks about Guy’s innovative style of string bending on stage. Guy had the ability to extract multiple notes from a single string while pushing the feedback to its absolute limits.

One of the most eye-opening and yet most peculiar revelations of Blues Chase The Blues Away captures the irony of Guy’s influence. His heavy, kinetic blues licks didn’t make it to the States, but after vacationing in England in 1965, he discovered that British guitar stars are waiting – Jeff Beck, Eric Clapton, and Jimmy Page among them – everyone had listened to him and became superstars by following his example.

When they hit hits in America, they couldn’t believe that pop music fans in the States didn’t know who Guy was when they had him all along.

Commentators on the documentary compare Guy’s guitar playing skills to the unforgiving violence of a natural disaster. Carlos Santana compared it to “a tornado or a hurricane” while John Mayer called the sound of his guitar behind the stage a “Sonic Tsunami”.

The narrative of the film is held together by a video motif of testimonials, “The Blues According to …” followed by words from players like Hopkins, Dixon, Waters to Clapton, Clark and Mayer about what the blues meant to them. Each of their interpretations was different, and yet they were all true.

In addition, it expertly set the tone for what will come on Guy’s journey. Decades of touring overseas with people like that Grateful dead, championed by The Rolling Stones and Stevie Ray Vaughn and then won the first of these nine Grammys in 1991!

The story culminates in his appearance at a blues tribute special at the White House with President Barack Obama. Blues chases away the blues is an amazing rendering of music originals like Guy that gives us the chance to honor him while we still have him and do what he did: honor those he admired.

And the best part about it? He has to tell the story himself.

Blues Chase The Blues Away can be streamed on Tribeca until June 23rd.

Have you subscribed theGrios Podcast “Dear culture”? Download our latest episodes now!

TheGrio is now available on Apple TV, Amazon Fire, and Roku. Download theGrio today!

]]> 0
Canada needs to step up its biopharmaceutical game Thu, 17 Jun 2021 21:52:02 +0000 It has been said over and over again over the past few months, but it needs to be repeated: The development of COVID-19 vaccines that are now being used is a testament to the collaboration and innovation of industries and governments. It underlines the art of the possible. Of the myriad of concerns raised by […]]]>

It has been said over and over again over the past few months, but it needs to be repeated: The development of COVID-19 vaccines that are now being used is a testament to the collaboration and innovation of industries and governments. It underlines the art of the possible. Of the myriad of concerns raised by the pandemic, access to these vaccines, as well as to treatments and diagnoses, remain at the fore of heads of state and government. We saw that at the G7 summit over the weekend.

In some countries, timely access to COVID vaccines is promoted by strong domestic pharmaceutical research and development (R&D), manufacturing, and excellent industry-government relationships. I think of Israel and Great Britain. In Canada, we have the opportunity to better prepare for the inevitable need for these drugs in the future. By strengthening our capacities to manufacture our own pharmaceuticals, we would be less dependent on massive procurement efforts in a pandemic situation. Canadians would have early access to medicines and our country could become a world leader in this area.

However, access to new drugs is not just about responding to global pandemics.

Our cautious optimism while waiting for vaccine deliveries from abroad gives us all a sense of what Canadians with a rare disease have to endure while waiting for the latest treatment to be available here. Because of this, it is important that industry, government and all health care players work together to improve Canada’s life science sector, which includes our domestic R&D and bio-manufacturing capabilities.

But to build a strong and sustainable life sciences sector, we have to “start with a stop”. Therefore Innovative Medicines Canada (IMC) demanded the federal government halt the implementation of the regulatory changes to the patented drug pricing review board due to take effect on July 1st.

Simply put, these changes will have unfortunate consequences that will put Canada and Canadians at a disadvantage.

Lowering certain drug prices by 40 to 90 percent will further deter companies from introducing or investing in new products in the Canadian market. The displacement of business from Canada also means fewer clinical trials, less in-house research and development – and most importantly, less access for Canadians to the latest drugs. As things stand, Canadians only have access to 48 percent of all new drugs available worldwide.

There is much to be gained from stopping to assess this impact, and even more so when positioning Canada to compete and rise as a global leader in the life sciences. We start economically on a good basis.

Statistics Canada published in April a report on Contribution of pharmaceutical activity to the Canadian economy. The report shows that Canada’s innovative pharmaceutical sector supports more than 100,000 high quality full-time jobs. It also generates nearly $ 15 billion in economic activity in Canada and invests nearly $ 2 billion in research and development.

Canada are in an enviable position and should play to their strengths.

We have universities and colleges with recognized medical, biomedical, software and computer engineering faculties. We have expertise in high quality clinical trials and existing biopharmaceutical clusters in Ontario and Quebec. We have solid public health systems and infrastructure. And we have new innovation clusters in the fields of regenerative medicine, oncology, infectious diseases, metabolic diseases, neurodegeneration, artificial intelligence, stem cell therapy, genomics and personalized medicine.

IMC members also have significant partnerships with Canadian hospitals and universities. According to Statistics Canada, 90 percent of the $ 144 million R&D outsourced to Canadian hospitals and universities by innovative pharmaceutical companies came from IMC members.

The positive recognition in the 2021 federal budget and the commitment of the Minister for Innovation, Science and Industry, Francois-Philippe Champagne, to strengthening organic production in Canada are encouraging steps. Essentially, we have what it takes to be an attractive country to invest in and the opportunity to work together to build it a strong life sciences sector.

It starts with government, industry, the research community, patient groups, and others working together to address years of policy making that have made Canada less attractive to industrial investment and commercial activity. In particular, it requires that we work collectively to address the fundamental issues that: discourage major investment, stave off research and development that drives innovation, and threaten clinical trials and access to medicines in Canada.

As vaccines tap economies around the world, we are witnessing the power of accessible vaccines and the benefits of resilient working relationships.

Right now Canada is losing the value of a strong life sciences sector that includes greater government-industry collaboration. Let’s not give up the potential of high paying jobs, indigenous R&D, and most importantly, life saving treatments for Canadians.

The development of COVID-19 vaccines has shown the world the art of the possible. Now is the time for Canada to do the same.

The photo for this column was changed on June 17th after it was published.

Pamela Fralick is President of Innovative Medicines Canada, an industry association that works with members and communities to ensure Canadians have access to the medicines they need at all times.

The views, opinions, and positions of all iPolitics columnists and contributors are those of the author alone. They do not inherently or expressly reflect the views, opinions and / or positions of iPolitics.

More from iPolitics

]]> 0